Literature DB >> 2262248

Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study.

R Scragg1, R Jackson, I M Holdaway, T Lim, R Beaglehole.   

Abstract

The relation between the plasma level of 25-hydroxyvitamin D3, the main metabolite of sun-induced vitamin D, and myocardial infarction (MI) was investigated in a community-based case-control study. Some 179 MI patients presenting to hospital within 12 hours of the onset of symptoms were individually matched with controls by age, sex and date of blood collection. MI patients had significantly lower mean 25-hydroxyvitamin D3 levels than controls (32.0 versus 35.5 nmol/L; p = 0.017), with the case-control differences being greatest in winter and spring. The relative risk of MI for subjects with 25-hydroxyvitamin D3 levels equal to or above the median was 0.43 (95% confidence limits = 0.27, 0.69) compared to subjects below the median. The decrease in MI risk associated with raised vitamin D3 levels was observed in all seasons. These results provide support for the hypothesis that increased exposure to sunlight is protective against coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2262248     DOI: 10.1093/ije/19.3.559

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  85 in total

1.  Are we really dying for a tan?

Authors:  A R Ness; S J Frankel; D J Gunnell; G D Smith
Journal:  BMJ       Date:  1999-07-10

2.  Inaccuracies in relating 25-hydroxyvitamin D to ischemic heart disease.

Authors:  Reinhold Vieth; D Sudhaker Rao
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

3.  Baseline Vitamin D Deficiency Decreases the Effectiveness of Statins in HIV-Infected Adults on Antiretroviral Therapy.

Authors:  Corrilynn O Hileman; Vin Tangpricha; Abdus Sattar; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731

Review 4.  The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action.

Authors:  Michael F Holick
Journal:  Mol Aspects Med       Date:  2008-09-02

5.  Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004.

Authors:  Michal L Melamed; Paul Muntner; Erin D Michos; Jaime Uribarri; Collin Weber; Jyotirmay Sharma; Paolo Raggi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-04-16       Impact factor: 8.311

6.  Association between serum 25-hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism.

Authors:  Marcella D Walker; Elaine Cong; Anna Kepley; Marco R Di Tullio; Tatjana Rundek; Shunichi Homma; James A Lee; Rui Liu; Polly Young; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2013-11-27       Impact factor: 5.958

Review 7.  The noncalciotropic actions of vitamin D: recent clinical developments.

Authors:  Naim M Maalouf
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-07       Impact factor: 2.894

8.  Serum 25-hydroxyvitamin d levels are not associated with subclinical vascular disease or C-reactive protein in the old order amish.

Authors:  Erin D Michos; Elizabeth A Streeten; Kathleen A Ryan; Evadnie Rampersaud; Patricia A Peyser; Lawrence F Bielak; Alan R Shuldiner; Braxton D Mitchell; Wendy Post
Journal:  Calcif Tissue Int       Date:  2009-01-16       Impact factor: 4.333

9.  Vitamin D protects human endothelial cells from H₂O₂ oxidant injury through the Mek/Erk-Sirt1 axis activation.

Authors:  Lorella Polidoro; G Properzi; F Marampon; G L Gravina; C Festuccia; E Di Cesare; L Scarsella; C Ciccarelli; B M Zani; C Ferri
Journal:  J Cardiovasc Transl Res       Date:  2012-12-18       Impact factor: 4.132

10.  Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial.

Authors:  Lars Rejnmark; Peter Vestergaard; Lene Heickendorff; Leif Mosekilde
Journal:  Int J Endocrinol       Date:  2009-07-21       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.